Blood advances
Journal
Overview
publication venue for
-
Aging cells, young patients: senescence in Hodgkin lymphoma..
10.
2026
-
Disordered differentiation and cellular senescence in pediatric Hodgkin Reed-Sternberg cells..
10.
2026
-
Factor VIII originates primarily from anatomically distinct subsets of liver sinusoidal endothelial cells..
10.
2026
-
Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.
2026
-
ASH ISTH 2026 guidelines for Anticoagulant Prophylaxis of Pediatric Patients at Risk of Venous Thromboembolism.
2026
-
Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia.
2026
-
Real-World Evidence for Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin in Classical Hodgkin Lymphoma.
2026
-
Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy in patients with myelofibrosis.
2026
-
Emapalumab use in malignancy-associated hemophagocytic lymphohistiocytosis in the United States: the REAL-HLH study..
10.
2026
-
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma..
10.
2026
-
Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyurea..
10.
2026
-
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma..
10.
2026
-
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy..
10.
2026
-
Safety, efficacy and patient-reported outcomes 6 years after fidanacogene elaparvovec in adults with hemophilia B.
2026
-
Patterns of Care and Clinical Outcomes in Systemic Peripheral T-cell Lymphoma: The LEO-MER Prospective Cohort Study.
2026
-
Derivation and external validation of a venous thromboembolism risk prediction model in asparaginase-treated ALL..
10.
2026
-
Multicenter initiative to standardize management of pediatric immune thrombocytopenia improves adherence to guidelines.
2026
-
Ectopic expression of BEX genes in T-cell acute lymphoblastic leukemia..
10.
2026
-
A Nested Case-Control Study of Monoclonal Gammopathy of Undetermined Significance in the Multiethnic Cohort Study.
2026
-
Safety and efficacy of daratumumab in immune thrombocytopenia..
10.
2026
-
Tumor-specific immune responses and biomarkers in pediatric patients with high-risk Hodgkin lymphoma..
10.
2026
-
High-grade B-cell lymphoma, not otherwise specified: an LLMPP study..
9.
2025
-
Bone marrow and blood demonstrate distinct immune reconstitution patterns and correlations with relapse posttransplant..
9.
2025
-
Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome..
9.
2025
-
BH3 mimetic drugs overcome the microenvironment-induced resistance to crizotinib in ALK+ anaplastic large cell lymphoma..
9.
2025
-
Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenström macroglobulinemia..
9.
2025
-
Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma..
9.
2025
-
Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL/SLL..
9.
2025
-
Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantation..
9.
2025
-
Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry..
9.
2025
-
Persistent postremission clonal hematopoiesis shapes the relapse trajectories of acute myeloid leukemia..
9.
2025
-
Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort study..
9.
2025
-
High pulmonary hypertension risk by echocardiogram shortens survival in polycythemia vera..
9.
2025
-
Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium..
9.
2025
-
The roadmap to integrate diversity, equity, and inclusion in hematology clinical trials: an American Society of Hematology initiative..
9.
2025
-
IDCH: is it now determined?.
9.
2025
-
Deficit accumulation frailty index and treatment tolerability in AML: data from CALGB 11001 and 11002 (Alliance)..
9.
2025
-
Targeting T cells with tetravalent bispecific antibodies for the treatment of graft-versus-host disease..
9.
2025
-
A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis..
8.
2024
-
Outcomes in children with provoked venous thrombosis and antiphospholipid antibodies: findings from the Kids-DOTT trial..
8.
2024
-
Rates of severe neutropenia and infection risk in patients treated with deferiprone: 28 years of data..
8.
2024
-
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy..
8.
2024
-
CD19-directed CART therapy for T-cell/histiocyte-rich large B-cell lymphoma..
8.
2024
-
Polygenic polymorphism is associated with NKG2A repertoire and influences lymphocyte phenotype and function..
8.
2024
-
What is in a name: defining pediatric refractory ITP..
8.
2024
-
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma..
8.
2024
-
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome..
8.
2024
-
The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts..
8.
2024
-
Somatic mutations in FAS pathway increase hemophagocytic lymphohistiocytosis risk in patients with T- and/or NK-cell lymphoma..
8.
2024
-
Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol..
8.
2024
-
An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL..
8.
2024
-
Racial/ethnic disparities in availability of volunteer unrelated donors for allogeneic transplantation..
8.
2024
-
A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia..
8.
2024
-
Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib..
8.
2024
-
Acute pulmonary injury in hematology patients supported with pathogen-reduced and conventional platelet components..
8.
2024
-
Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study..
8.
2024
-
Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis..
8.
2024
-
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial..
8.
2024
-
Congenital fibrinogen disorders: a retrospective clinical and genetic analysis of the Prospective Rare Bleeding Disorders Database..
8.
2024
-
Acute myeloid leukemia stratifies as 2 clinically relevant sphingolipidomic subtypes..
8.
2024
-
Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML..
8.
2024
-
High-risk and silent clonal hematopoietic genotypes in patients with nonhematologic cancer..
8.
2024
-
Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML..
8.
2024
-
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML..
8.
2024
-
Gender disparities in allograft access due to HLA-sensitization in multiparous women..
8.
2024
-
Resistance to PRMT5-targeted therapy in mantle cell lymphoma..
8.
2024
-
Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study..
7.
2024
-
Histiocytic neoplasm subtypes differ in their MAP2K1 mutational type..
7.
2023
-
Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms..
7.
2023
-
Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide-based transplant..
7.
2023
-
CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies..
7.
2023
-
Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma..
7.
2023
-
The bone marrow stroma in human myelodysplastic syndrome reveals alterations that regulate disease progression..
7.
2023
-
PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma..
7.
2023
-
Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories..
7.
2023
-
Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis..
7.
2023
-
Emergence of human CMV-induced NKG2C+ NK cells is associated with CD8+ T-cell recovery after allogeneic HCT..
7.
2023
-
Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma..
7.
2023
-
Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantation..
7.
2023
-
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study..
7.
2023
-
Immune profiling after allogeneic hematopoietic cell transplantation in pediatric acute myeloid leukemia..
7.
2023
-
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia..
7.
2023
-
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy..
7.
2023
-
How I read an article that uses machine learning methods..
7.
2023
-
Loss-of-function lesions impact B-cell development and fitness but are insufficient to drive CLL in mouse models..
7.
2023
-
Aberrant expression of GOLM1 protects ALK+ anaplastic large cell lymphoma from apoptosis by enhancing BCL-XL stability..
7.
2023
-
Analysis of disparities in time to allogeneic transplantation in adults with acute myelogenous leukemia..
7.
2023
-
Association between non-European ancestry, low socioeconomic status, and receipt of HLA-disparate allografts in adult BMT recipients..
7.
2023
-
Clonal hematopoiesis in survivors of childhood cancer..
7.
2023
-
Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma..
7.
2023
-
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS..
7.
2023
-
Role of NKG2D ligands and receptor in haploidentical related donor hematopoietic cell transplantation..
7.
2023
-
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates..
7.
2023
-
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome..
7.
2023
-
Comorbidities in transplant recipients with acute myeloid leukemia receiving low-intensity conditioning regimens: an ALWP EBMT study..
7.
2023
-
Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones..
7.
2023
-
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML..
7.
2023
-
FBXW7β isoform drives transcriptional activation of the proinflammatory TNF cluster in human pro-B cells..
7.
2023
-
Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia..
7.
2023
-
A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia..
7.
2023
-
Longitudinal study of 2 patients with cyclic thrombocytopenia, STAT3 and MPL mutations..
7.
2023
-
Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults..
6.
2022
-
Patient perspectives on testing for clonal hematopoiesis of indeterminate potential..
6.
2022
-
RUNX1 deficiency cooperates with SRSF2 mutation to induce multilineage hematopoietic defects characteristic of MDS..
6.
2022
-
Racial disparities in access to alternative donor allografts persist in the era of "donors for all"..
6.
2022
-
Hematopoietic fitness of JAK2V617F myeloproliferative neoplasms is linked to clinical outcome..
6.
2022
-
Phase 1/2 study of ixazomib with cyclophosphamide and dexamethasone in newly diagnosed AL amyloidosis..
6.
2022
-
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients..
6.
2022
-
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients..
6.
2022
-
Dominant epitopes presented by prevalent HLA alleles permit wide use of banked CMVpp65 T cells in adoptive therapy..
6.
2022
-
Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma..
6.
2022
-
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen..
6.
2022
-
Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatment..
6.
2022
-
Cell origin-dependent cooperativity of mutant Dnmt3a and Npm1 in clonal hematopoiesis and myeloid malignancy..
6.
2022
-
Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101..
6.
2022
-
Simplified detection of Epstein-Barr virus for diagnosis of endemic Burkitt lymphoma..
6.
2022
-
A genetically distinct pediatric subtype of primary CNS large B-cell lymphoma is associated with favorable clinical outcome..
6.
2022
-
Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness..
6.
2022
-
Myb drives B-cell neoplasms and myeloid malignancies in vivo..
6.
2022
-
Rapid next-generation sequencing aids in diagnosis of transient abnormal myelopoiesis in a phenotypically normal newborn..
6.
2022
-
TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML..
6.
2022
-
Clofarabine with topotecan, vinorelbine, and thiotepa reinduction regimen for children and young adults with relapsed AML..
6.
2022
-
Health-related quality of life and fatigue in children and adults with pyruvate kinase deficiency..
6.
2022
-
Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients..
6.
2022
-
The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT..
6.
2022
-
Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantation..
6.
2022
-
Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia..
6.
2022
-
Origins of bloodstream infections following fecal microbiota transplantation: a strain-level analysis..
6.
2022
-
Iron status influences the response of cord blood megakaryocyte progenitors to eltrombopag in vitro..
6.
2022
-
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML..
6.
2022
-
Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma..
5.
2021
-
ALCAM-EGFR interaction regulates myelomagenesis..
5.
2021
-
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies..
5.
2021
-
PD-1 inhibition in advanced myeloproliferative neoplasms..
5.
2021
-
Restriction of HIV-1 infection in sickle cell trait..
5.
2021
-
Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome..
5.
2021
-
Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease..
5.
2021
-
IFN-γ signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS..
5.
2021
-
Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells..
5.
2021
-
Loss of erythroblasts in acute myeloid leukemia causes iron redistribution with clinical implications..
5.
2021
-
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis..
5.
2021
-
Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation..
5.
2021
-
Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML..
5.
2021
-
Inhibiting autophagy targets human leukemic stem cells and hypoxic AML blasts by disrupting mitochondrial homeostasis..
5.
2021
-
ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia presenting in an infant: an entity distinct from JMML..
5.
2021
-
Prospective KIR genotype evaluation of hematopoietic cell donors is feasible with potential to benefit patients with AML..
5.
2021
-
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML..
5.
2021
-
American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19..
5.
2021
-
Adoptive therapy with CMV-specific cytotoxic T lymphocytes depends on baseline CD4+ immunity to mediate durable responses..
5.
2021
-
Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma..
5.
2021
-
A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant..
5.
2021
-
Dynamic changes in murine erythropoiesis from birth to adulthood: implications for the study of murine models of anemia..
5.
2021
-
High progression-free survival after intermediate intensity double unit cord blood transplantation in adults..
4.
2020
-
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease..
4.
2020
-
Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub..
4.
2020
-
The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development..
4.
2020
-
Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma..
4.
2020
-
Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response..
4.
2020
-
Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes..
4.
2020
-
Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase..
4.
2020
-
HLA-A alleles influencing NK cell function impact AML relapse following allogeneic hematopoietic cell transplantation..
4.
2020
-
T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma..
4.
2020
-
JAK2S523L, a novel gain-of-function mutation in a critical autoregulatory residue in JAK2V617F- MPNs..
4.
2020
-
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia..
4.
2020
-
American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults..
4.
2020
-
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies..
4.
2020
-
Rapidly expanded partially HLA DRB1-matched fungus-specific T cells mediate in vitro and in vivo antifungal activity..
4.
2020
-
DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality..
4.
2020
-
Patterns of salivary microbiota injury and oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation..
4.
2020
-
Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report..
4.
2020
-
Specific patterns of H3K79 methylation influence genetic interaction of oncogenes in AML..
4.
2020
-
Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure..
4.
2020
-
Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms..
4.
2020
-
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML..
4.
2020
-
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia..
4.
2020
-
CpG methylation in cell-free Epstein-Barr virus DNA in patients with EBV-Hodgkin lymphoma..
4.
2020
-
Comprehensive proteomic analysis of murine terminal erythroid differentiation..
4.
2020
-
Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia..
4.
2020
-
Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management..
4.
2020
-
KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation..
4.
2020
-
Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL..
4.
2020
-
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation..
4.
2020
-
Robust CD4+ T-cell recovery in adults transplanted with cord blood and no antithymocyte globulin..
4.
2020
-
Primary central nervous system lymphoma: initial features, outcome, and late effects in 75 children and adolescents..
3.
2019
-
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes..
3.
2019
-
End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings..
3.
2019
-
Inhibition of the mutated c-KIT kinase in AML1-ETO-positive leukemia cells restores sensitivity to PARP inhibitor..
3.
2019
-
Cranberry A-type proanthocyanidins selectively target acute myeloid leukemia cells..
3.
2019
-
ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants..
3.
2019
-
Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia..
3.
2019
-
Challenges and approaches to implementing master/basket trials in oncology..
3.
2019
-
Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition..
3.
2019
-
External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation..
3.
2019
-
Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning..
3.
2019
-
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies..
3.
2019
-
Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission..
3.
2019
-
A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL..
3.
2019
-
Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia..
3.
2019
-
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib..
3.
2019
-
Antirelapse effect of pretransplant exposure to rabbit antithymocyte globulin..
3.
2019
-
Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms..
3.
2019
-
CD34+ cell content of 126 341 cord blood units in the US inventory: implications for transplantation and banking..
3.
2019
-
A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease..
3.
2019
-
Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia..
3.
2019
-
Racial disparities in access to HLA-matched unrelated donor transplants: a prospective 1312-patient analysis..
3.
2019
-
Targeting CD47 in Sézary syndrome with SIRPαFc..
3.
2019
-
Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model..
3.
2019
-
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma..
3.
2019
-
MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas..
3.
2019
-
Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma..
3.
2019
-
Burden and impact of multifactorial geriatric syndromes in allogeneic hematopoietic cell transplantation for older adults..
3.
2019
-
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)..
2.
2018
-
Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms..
2.
2018
-
PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation..
2.
2018
-
Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia..
2.
2018
-
Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802..
2.
2018
-
In silico prediction of nonpermissive HLA-DPB1 mismatches in unrelated HCT by functional distance..
2.
2018
-
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort..
2.
2018
-
Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission..
2.
2018
-
Severely impaired terminal erythroid differentiation as an independent prognostic marker in myelodysplastic syndromes..
2.
2018
-
A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia..
2.
2018
-
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort..
2.
2018
-
Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis..
2.
2018
-
Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma..
2.
2018
-
Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity..
2.
2018
-
Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia..
2.
2018
-
The human IL-15 superagonist ALT-803 directs SIV-specific CD8+ T cells into B-cell follicles..
2.
2018
-
Catalyzing innovation in clinical trial design and analysis at NHLBI: a funding opportunity for clinical trials in blood disorders..
1.
2017
-
Constitutive Ras signaling and Ink4a/Arf inactivation cooperate during the development of B-ALL in mice..
1.
2017
-
Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy..
1.
2017
-
Progressive multifocal leukoencephalopathy and hematologic malignancies: a single cancer center retrospective review..
1.
2017
-
Whole-exome sequencing in evaluation of patients with venous thromboembolism..
1.
2017
-
Implications of the US Food and Drug Administration draft guidance for mitigating septic reactions from platelet transfusions..
1.
2017
-
Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma..
1.
2016
-
Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination..
1.
2016
-
Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment..
1.
2016
-
Accurate analysis of race/ethnicity and socioeconomic status..
8.
2024
-
Unexpected diagnosis of WHIM syndrome in refractory autoimmune cytopenia..
8.
2024
-
Inaccuracies in assignment of patient race and ethnicity: implications for unrelated donor searches and health care delivery..
7.
2023
-
Direct oral anticoagulants in sickle cell disease: a systematic review and meta-analysis..
6.
2022
-
Successful treatment and integrated genomic analysis of an infant with FIP1L1-RARA fusion-associated myeloid neoplasm..
6.
2022
-
A JAK2/IDH1-mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN..
4.
2020
-
Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies..
3.
2019
-
Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma..
3.
2019
-
Evolution of a chemosensitive core-binding factor AML into an aggressive leukemia with eosinophilic differentiation..
2.
2018
-
Embarrassment of riches: which donor for allo-transplant?.
9.
2025
-
Under AI's lens: spotting mutations visually..
8.
2024
-
Toward new therapy end points in polycythemia vera: targeting clonal and inflammatory pathways.
2026
-
Comparative infection risk in CAR T vs bispecific antibodies in B-cell lymphoma: a systematic review and meta-analysis.
2025
-
Efficacy and safety of thrombolysis for pediatric venous thromboembolism: a systematic review and meta-analysis.
2025
-
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients.
2025
-
American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summary.
2025
-
Optimizing liver health before and after gene therapy for hemophilia A.
2024
-
Cytoreductive therapy in younger adults with polycythemia vera: a meta-analysis of safety and outcomes.
2024
-
Retrospective characterization of nodal marginal zone lymphoma.
2023
-
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis.
2022
-
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients.
2021
-
Fetal/neonatal alloimmune thrombocytopenia: a systematic review of impact of HLA-DRB3*01:01 on fetal/neonatal outcome.
2020
-
Updated international consensus report on the investigation and management of primary immune thrombocytopenia.
2019
-
Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis.
2018
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)